← Back to Search

A Study of LY3473329 in Healthy Japanese Participants

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 through day 43

Summary

This trial tests a new drug, LY3473329, in healthy Japanese participants to see if it is safe and how the body handles it. Researchers will measure how quickly it enters the bloodstream and how long it stays in the body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 through day 43
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 through day 43 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary study objectives
PK: Maximum Concentration (Cmax) of LY3473329
PK: Time to Maximum Concentration (Tmax) of LY3473329
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3473329

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3473329Experimental Treatment1 Intervention
LY3473329 administered orally.
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3473329
2023
Completed Phase 2
~410

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,360 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,391 Previous Clinical Trials
428,817 Total Patients Enrolled
~6 spots leftby Dec 2025